DuPont (NYSE: DD), a producer of silicone-based technology and innovations for healthcare, is making significant investments in both capital and resources to strengthen strategic capabilities of its Liveo brand healthcare silicone solutions. Underscoring its long-term commitment to the healthcare industry – and confidence in its growth potential – DuPont is investing in innovation, as well as in manufacturing capabilities. These investments are focused on accelerating business growth, addressing key industry challenges arising from global megatrends and continually improving and expanding DuPont’s ability to serve customers.

“We are working in close collaboration with our key customers to help support and drive their leadership in key healthcare industry market segments,” said DuPont Liveo Healthcare Global Business Director Eugenio Toccalino. “As a leader in Biopharma Processing, Pharma Solutions and Medical Devices, we want to enable our customers to achieve a competitive edge and grow their business in these segments. Our customers fully appreciate and reward the value of our specialists and our full commitment to the needs of the healthcare industry all the way down to the patients.”

To support customer growth and accelerate new product introductions, the targeted investments include increasing supply capacities with manufacturing improvements at DuPont’s Healthcare Industries Materials Site (HIMS) in Hemlock, Mich. Notable upgrades include extrusion capacity expansion for tubing, a new ISO 7 cleanroom and ongoing elastomer capacity expansions with new mixing equipment for liquid silicone rubber (LSR) and high-consistency rubber (HCR).

These investments are critical for DuPont Liveo to continue addressing the key challenges and opportunities in three primary healthcare market segments, namely:

•   Biopharma Processing, to enable cost-effective, safe manufacturing of biologics used in innovative drugs and vaccines with a wide range of Liveo pharma tubing and overmolded assemblies.
•   Pharmaceutical Solutions, to enable safe, effective new therapeutic drug delivery routes with a unique offering in topical and transdermal solutions, and gastrointestinal active pharmaceutical ingredients.
•    Medical Devices, to enable safe, convenient and effective diagnostics, monitoring and treatment at the point of care with a broadening range of specialty medical adhesives and elastomers to support the trend for connected devices and wearables.

“Without question, these investments in the future of healthcare will help strengthen and grow the value of our DuPont Liveo brand healthcare silicone solutions,” Toccalino says. “We believe that DuPont Healthcare will have a positive impact on every level of the healthcare industry value chain.”

For more information, visit liveo.dupont.com